RT @AnandRotte: Happy to share that my review on combination of #CTLA4 & #PD1 blockers got 500 citations (source: @researchgate). Many than…
RT @AnandRotte: Happy to share that my review on combination of #CTLA4 & #PD1 blockers got 500 citations (source: @researchgate). Many than…
Happy to share that my review on combination of #CTLA4 & #PD1 blockers got 500 citations (source: @researchgate). Many thanks to reviewers & editors @JournalofExper1 for the feedback & opportunity Link to the article: https://t.co/09f8sNWQmP #i
RT @AnandRotte: Thank you #JECCR for the opportunity and recognition! Sincerely recommend @JournalofExper1 for publishing high quality res…
RT @JournalofExper1: For the beginning of 2021 the Review highlighted on JECCR web site https://t.co/xVWlRe1ZKU is the most cited one in 20…
Thank you #JECCR for the opportunity and recognition! Sincerely recommend @JournalofExper1 for publishing high quality research. Constructive & top quality feedback; fast turnaround time (25 d for 1st round); Imp factor (7.06) is decent #CancerResearc
RT @JournalofExper1: TOP 3 Most Cited 2019 1. Combination of CTLA-4 and PD-1 blockers for treatment of cancer https://t.co/s44l22UaN1 2.…
RT @JournalofExper1: For the beginning of 2021 the Review highlighted on JECCR web site https://t.co/xVWlRe1ZKU is the most cited one in 20…
For the beginning of 2021 the Review highlighted on JECCR web site https://t.co/xVWlRe1ZKU is the most cited one in 2019. 🍾 Congratulations to @AnandRotte 👉Combination of 𝐂𝐓𝐋𝐀-𝟒 and 𝐏𝐃-𝟏 𝐛𝐥𝐨𝐜𝐤𝐞𝐫𝐬 for treatment of cancer #Immunotherapy https://t.co/k0K3I
RT @JournalofExper1: TOP 3 Most Cited 2019 1. Combination of CTLA-4 and PD-1 blockers for treatment of cancer https://t.co/s44l22UaN1 2.…
RT @JournalofExper1: TOP 3 Most Cited 2019 1. Combination of CTLA-4 and PD-1 blockers for treatment of cancer https://t.co/s44l22UaN1 2.…
TOP 3 Most Cited 2019 1. Combination of CTLA-4 and PD-1 blockers for treatment of cancer https://t.co/s44l22UaN1 2. Advances in cancer immunotherapy 2019 https://t.co/TdRfZXS0Zq 3. STAT3 as a potential therapeutic target in triple negative breast cancer
RT @JournalofExper1: The most cited REVIEW of 2019 🏆🏆🏆 @AnandRotte ➡️ 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐓𝐋𝐀-𝟒 𝐚𝐧𝐝 𝐏𝐃-𝟏 𝐛𝐥𝐨𝐜𝐤𝐞𝐫𝐬 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 #I…
@AnandRotte
The most cited REVIEW of 2019 🏆🏆🏆 @AnandRotte ➡️ 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐓𝐋𝐀-𝟒 𝐚𝐧𝐝 𝐏𝐃-𝟏 𝐛𝐥𝐨𝐜𝐤𝐞𝐫𝐬 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 #Immunotherapy #CTLA4 #PD1 #CombinationTherapy Enjoy your reading 🧑💻 https://t.co/k0K3IP98lW https://t.co/OgGjrFv9GA
RT @AnandRotte: Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immun…
RT @AnandRotte: Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immun…
RT @AnandRotte: Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immun…
Nice overview on #aCTLA4 (Ipi): https://t.co/Tkr2aqYEt2
RT @AnandRotte: Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immun…
RT @AnandRotte: Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immun…
RT @ingentium_mel: Combination of CTLA-4 and PD-1 blockers for treatment of #cancer. https://t.co/LBS3g0JP7Z
Combination of CTLA-4 and PD-1 blockers for treatment of #cancer. https://t.co/LBS3g0JP7Z
Check out my new review article 'Combination of CTLA-4 and PD-1 blockers for treatment of cancer' published at JECCR #immunotherapy #PD1 #CTLA4 #OpenAccess https://t.co/BKgJIiLgIQ